Form 4: Neurocrine Biosciences CMO Equity Vesting Update

Chief Medical Officer Sanjay Keswani acquired 3,212 shares of Neurocrine Biosciences common stock via RSU vesting.

Summary

• Chief Medical Officer Sanjay Keswani vested 3,212 restricted stock units (RSUs) on June 2, 2026.
• The company withheld 1,733 shares to satisfy tax obligations related to the vesting event.
• The net result was an increase of 1,479 shares in the reporting person's direct ownership.
• The transaction was executed at a reference price of $154.84 per share for tax withholding purposes.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard executive compensation vesting rather than a discretionary trade.

Positives

• The transaction reflects standard equity compensation vesting for a key executive.
• No open market sales were conducted by the executive.

Negatives

• The company withheld 1,733 shares to cover tax liabilities, which is a standard but non-cash-generating event for the executive.

Risks

• Future vesting is subject to continued employment and the terms of the original RSU grant.

Future Outlook

The reporting person holds 9,634 unvested RSUs scheduled to vest annually through June 2, 2029.

Management Comments

• No specific management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of executive compensation and does not signal a change in corporate strategy or market sentiment.

Comparison to Industry Standards

• The use of net-settlement (withholding shares for taxes) is a standard industry practice for executive equity compensation in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Future vesting of remaining 9,634 RSUs scheduled for June 2027, 2028, and 2029.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Insider Trading, Form 4, Equity Compensation, Chief Medical Officer